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Purpose of the study
To compare continuous HAART with a CD4-driven STI
strategy.
Methods
LOTTI is a randomized, controlled, prospective trial.
Patients with HIV-RNA <50 copies/ml and CD4 counts
>700 cells/mcL were randomised to continue HAART or
to stop it; 350 cells/mcL was the immunologic threshold
to resume HAART. The primary end-point is clinical:
development of any opportunistic disease, death from
any cause, or the occurrence of diseases, other than oppor-
tunistic, requiring hospital admission. Secondary end-
points are major adverse effects, virologic failures and
therapeutic costs. An interim ITT analysis at 4-years fol-
low-up is presented.
Summary of results
329 patients were randomized. The total follow-up time is
1,388 person-years. Patients in the STI group performed a
total of 241 STI cycles. On average, patients in the STI
group were on HAART for 34.7% (mean 515 days) of fol-
low-up time, in the control group this value raised to
98.3% (mean 1,530 days). The primary end point of the
study occurred in 12.1% of patients on STI and in 11.6%
of controls (OR 1.05; 95% CI 0.5–2.1). The 95% CI for
the difference between groups was far below the pre-
defined 12% limit assumed to define equivalence. Resist-
ance-conferring mutations were selected in 4.8% of STI
patients and in 6.7% of controls (OR 0.79; 95% CI 0.3–
1.8). Grade 3 or 4 adverse events were observed in 27.4%
of controls and only in 20.6% of patients in the STI group.
The mean daily total cost for controls was 20.29 euros and
it dropped to 9.07 euros in the STI arm (p < 0.0001).
Conclusion
CD4-guided STIs may be a possible alternative strategic
option for chronically infected individuals responding to
HAART provided that CD4 decrements would be steadily
maintained above a safe threshold. STIs warrant further
careful prospective evaluation especially to investigate
virologic and clinical outcomes in the very long period.
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